From: MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis
 | Healthy controls | Patient |
---|---|---|
Total number | 10 | 14 |
Age, mean (range) years* | 51 (25 to 65) | 55 (31 to 68) |
Male, number (%)* | 10 (100) | 14 (100) |
Duration of acute gout, mean (range) days | NA | 2 (1 to 4) |
Co-morbidity | NA | Â |
  Diabetes, number (%) |  | 3 (21.4) |
  Hypertension, number (%) |  | 4 (28.5) |
  Hypercholesterolemia, number (%) |  | 1 (7.1) |
  Cardiovascular disease, number (%) |  | 2 (14.3) |
Current medicines | NA | Â |
  Naive, number (%) |  | 14 (100) |
Location of arthritis | NA | Â |
  First MTP joint, number (%) |  | 10 (71.4) |
  Knee joint, number (%) |  | 12 (72.3) |
  Ankle joint, number (%) |  | 2 (14.3) |
Serum urate level, mean (range) mg/dl | NA | 7 (5 to 12) |
ESR, mean (range, mm/h) | NA | 55 (45 to 61) |
CRP, mean (range, mg/dL) | NA | 12.5 (5.8 to 18.3) |